China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)
China · Delayed Price · Currency is CNY 18.56
+0.15 (0.81%)
Apr 8, 2026, 3:00 PM CST
SHA:600062 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 10,881 | 11,119 | 11,177 | 9,522 | 9,034 |
Other Revenue | 119.54 | 92.76 | 133.12 | 102.99 | 77.88 |
| 11,001 | 11,212 | 11,310 | 9,625 | 9,112 | |
Revenue Growth (YoY) | -1.88% | -0.87% | 17.50% | 5.64% | 7.14% |
Cost of Revenue | 4,660 | 4,832 | 4,904 | 4,307 | 4,048 |
Gross Profit | 6,341 | 6,380 | 6,406 | 5,318 | 5,064 |
Selling, General & Admin | 4,006 | 4,127 | 3,937 | 3,478 | 3,502 |
Research & Development | 531.6 | 555.19 | 627.85 | 482.48 | 409.59 |
Other Operating Expenses | 88.57 | 75.98 | 106.24 | 119.35 | 115.75 |
Operating Expenses | 4,635 | 4,739 | 4,681 | 4,081 | 4,029 |
Operating Income | 1,706 | 1,641 | 1,725 | 1,237 | 1,034 |
Interest Expense | -33.58 | -15.36 | -15.4 | -10.62 | -11.62 |
Interest & Investment Income | 164.93 | 198.56 | 190.56 | 89.68 | 81.55 |
Earnings From Equity Investments | - | - | - | 16.23 | - |
Currency Exchange Gain (Loss) | -3.53 | 9.19 | 6.6 | 18.06 | -4.97 |
Other Non Operating Income (Expenses) | 1.25 | 29.93 | 61.3 | 6.36 | 0.26 |
EBT Excluding Unusual Items | 1,836 | 1,863 | 1,968 | 1,357 | 1,099 |
Impairment of Goodwill | - | -29.41 | -28.9 | - | -56.68 |
Gain (Loss) on Sale of Investments | 1.83 | -1.64 | 13.7 | 5.99 | 35.36 |
Gain (Loss) on Sale of Assets | -10.1 | 46.84 | 0.18 | -2.27 | 1.03 |
Asset Writedown | -22.76 | -59.17 | -57.52 | -8.43 | -0.54 |
Other Unusual Items | 106.25 | 46.61 | 40.85 | 82.76 | 42.65 |
Pretax Income | 1,911 | 1,867 | 1,937 | 1,435 | 1,121 |
Income Tax Expense | 227.52 | 215.94 | 272.71 | 201.27 | 149.06 |
Earnings From Continuing Operations | 1,683 | 1,651 | 1,664 | 1,234 | 972.13 |
Minority Interest in Earnings | -36.27 | -23.02 | 6.29 | -53.59 | -36.45 |
Net Income | 1,647 | 1,628 | 1,670 | 1,180 | 935.69 |
Net Income to Common | 1,647 | 1,628 | 1,670 | 1,180 | 935.69 |
Net Income Growth | 1.18% | -2.55% | 41.55% | 26.12% | -6.91% |
Shares Outstanding (Basic) | 1,033 | 1,028 | 1,024 | 1,036 | 1,043 |
Shares Outstanding (Diluted) | 1,034 | 1,028 | 1,024 | 1,036 | 1,043 |
Shares Change (YoY) | 0.61% | 0.33% | -1.07% | -0.74% | - |
EPS (Basic) | 1.59 | 1.58 | 1.63 | 1.14 | 0.90 |
EPS (Diluted) | 1.59 | 1.58 | 1.63 | 1.14 | 0.90 |
EPS Growth | 0.57% | -2.87% | 43.09% | 27.06% | -6.91% |
Free Cash Flow | 869.88 | 1,188 | 1,245 | 889.57 | 849.25 |
Free Cash Flow Per Share | 0.84 | 1.16 | 1.22 | 0.86 | 0.81 |
Dividend Per Share | 0.479 | 0.471 | 0.257 | 0.578 | 0.480 |
Dividend Growth | 1.70% | 83.27% | -55.54% | 20.42% | 65.52% |
Gross Margin | 57.64% | 56.91% | 56.64% | 55.25% | 55.57% |
Operating Margin | 15.51% | 14.64% | 15.26% | 12.85% | 11.35% |
Profit Margin | 14.97% | 14.52% | 14.77% | 12.26% | 10.27% |
Free Cash Flow Margin | 7.91% | 10.59% | 11.01% | 9.24% | 9.32% |
EBITDA | 2,460 | 2,370 | 2,390 | 1,778 | 1,482 |
EBITDA Margin | 22.36% | 21.14% | 21.13% | 18.47% | 16.26% |
D&A For EBITDA | 753.81 | 728.93 | 664.52 | 540.36 | 447.4 |
EBIT | 1,706 | 1,641 | 1,725 | 1,237 | 1,034 |
EBIT Margin | 15.51% | 14.64% | 15.26% | 12.85% | 11.35% |
Effective Tax Rate | 11.91% | 11.57% | 14.08% | 14.03% | 13.30% |
Revenue as Reported | 11,001 | 11,212 | 11,310 | 9,625 | 9,112 |
Advertising Expenses | 79.39 | 85.96 | 35.82 | - | - |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.